Adverse reactions of zanamivir

This product is ineffective for patients with asthma or chronic obstructive pulmonary disease, and may even lead to danger. Literature reports that patients with mild to moderate asthma can cause bronchospasm after using this product, and patients who cause bronchospasm should stop taking the drug and inform their attending doctors. When patients with respiratory diseases take zanamivir, they should have inhaled quick-acting bronchodilators around them.

Other adverse reactions of taking this medicine include: headache, diarrhea, nausea, vomiting, dizziness, etc. The incidence is less than 2%, and most of them are mild reactions.

Animal experiments show that zanamivir has no carcinogenic, teratogenic and mutagenic effects and no reproductive toxicity. Zanamivir can cross the placental barrier in animal experiments, and the fetal blood concentration is significantly lower than that of the mother. Lack of sufficient and effective research results to confirm the pharmacokinetics of pregnant women, so we should weigh the impact on the fetus when using it. Zanamivir was detected in the milk of lactating rats. However, it is uncertain whether there is a drug in human milk, so lactating women should use this drug with caution. The adverse reactions of this product to the elderly and children under 12 years old are uncertain.

No obvious drug interaction was found in vitro study. This product does not affect liver microsomal enzymes, nor is it the substrate of P450 enzymes.